-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Makes a Striking Appearance at the 21st China International API Expo
Category:
发布时间：2023-06-23
【概要描述】
On June 19, the 21st CPHI China 2023—World Pharmaceutical Ingredients Exhibition—and the 16th PMEC China 2023—World Pharmaceutical Machinery, Packaging Equipment and Materials Exhibition—grandly opened at the Shanghai New International Expo Center in Pudong. Shijiazhuang Sihua Pharmaceutical Group’s API Division, together with the group’s Bosheng Medical Devices domestic and international sales teams, made a striking appearance with a range of new products.
On June 19, the 21st CPHI China 2023—World Pharmaceutical Ingredients Exhibition—and the 16th PMEC China 2023—World Pharmaceutical Machinery, Packaging Equipment and Materials Exhibition—grandly opened at the Shanghai New International Expo Center in Pudong. Shijiazhuang Sihua Pharmaceutical Group’s API Division, together with the group’s Bosheng Medical Devices domestic and international sales teams, made a striking appearance with a range of new products.
According to reports, the three-day exhibition spans 200,000 square meters and has attracted more than 3,000 domestic and international suppliers, as well as over 55,000 professional visitors and business delegates from home and abroad.
At the exhibition, business delegates from both China and abroad stopped by Shijiazhuang Sihua Pharmaceutical’s specially designed booth to learn more and explore potential business collaborations. Relevant executives and sales representatives from the group briefed attendees on the company’s innovative development initiatives and highlighted the competitive advantages of its specialty formulations, bulk active pharmaceutical ingredients, and pharmaceutical packaging materials. “After a two-year hiatus, it’s truly exciting to reconnect with Shijiazhuang Sihua Pharmaceutical and see such a wide array of new products on display,” remarked a Southeast Asian importer during a conversation with the group’s international trade team. “Shijiazhuang Sihua’s growth has opened up even more opportunities for collaboration.” During the event, the group garnered significant attention from industry professionals, engaged in discussions and exchanges with over 200 existing and new clients, distributed more than 500 copies of product brochures, and secured or preliminarily agreed upon approximately 20 business partnerships.
During the exhibition, relevant personnel from the Group also attended a series of events organized by the China Association of Pharmaceutical Commerce, including the 12th China–World Pharmaceutical Entrepreneurs Summit and the 2023 CPHI China–World International Regulatory Q&A Session. These sessions provided valuable insights into the latest international market trends, updates on international registration and audit regulations and policies, and opportunities for networking and dialogue with participating companies to explore potential avenues for future business collaboration.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has focused on international market operations, implementing a range of measures to accelerate its “going global” strategy. These include recruiting foreign trade professionals, obtaining international quality certifications and undergoing audits, expanding overseas product registrations, and proactively adapting to evolving international trade regulations. As a result, the group’s finished dosage forms are now sold in nearly 100 countries and regions worldwide, while its active pharmaceutical ingredients are highly regarded in more than 40 countries.
According to reports, CPHI & PMEC China has steadily evolved into an industry benchmark characterized by professionalism, internationalization, and high-end positioning. Over the years, the exhibition has expanded to cover 15 key sub-sectors across the entire pharmaceutical value chain, with exhibits spanning pharmaceutical raw materials, intermediates and fine chemicals, pharmaceutical excipients, finished dosage forms, biopharmaceuticals, packaging materials, laboratory instruments, and environmental protection and cleanroom solutions—gaining widespread attention and recognition from companies and professionals worldwide.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091